Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 4 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 221Carboplatin 216Cisplatin 203Paclitaxel 181Gemcitabine 148Docetaxel 126Capecitabine 112Pemetrexed 101Dexamethasone 101Cyclophosphamide 101Specimen Handling 98Oxaliplatin 96Magnetic Resonance Spectroscopy 96Radiotherapy 93Doxorubicin 90Fluorouracil 88Bevacizumab 85Nivolumab 73Leucovorin 73Rituximab 71Vincristine 68durvalumab 67Lenalidomide 64Radiation 63atezolizumab 61Irinotecan 61Etoposide 59130-nm albumin-bound paclitaxel 58Prednisone 55Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × montelukast × 1 year × Clear all
NCT04270409 2025-12-12

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Sanofi

Phase 3 Active not recruiting
337 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡